The Centers for Medicare & Medicaid Services (CMS) has launched a temporary pilot program providing eligible seniors fixed-cost access to GLP-1 weight-loss medications.
This initiative removes significant financial barriers for older adults seeking obesity treatments. By capping costs, the federal government aims to improve weight-loss outcomes for a population that has historically struggled to obtain these high-cost medications.
Dr. Mehmet Oz, the Administrator of CMS, said the program began on July 1, 2026 [2]. The pilot is scheduled to run from July 2026 through 2027 [3]. Under the terms of the program, eligible beneficiaries will pay a fixed price of $50 per month [1] for the medications.
The pilot covers several prominent GLP-1 drugs, including Wegovy, Zepbound, and Foundayo [4]. It also includes other GLP-1 offerings from manufacturers Novo Nordisk and Eli Lilly [4].
CMS designed the program to provide affordable access to drugs that have been difficult for seniors to obtain. The agency said it intends to use the pilot to evaluate how improved access to obesity treatment affects the overall health of the Medicare population.
The program operates through the federal Medicare system in the U.S. [5]. While the fixed cost provides immediate relief to patients, the temporary nature of the pilot means the long-term availability of these subsidies remains undecided.
“Eligible beneficiaries will pay a fixed price of $50 per month”
This pilot represents a significant shift in federal health policy by treating obesity as a primary target for Medicare subsidies. By drastically lowering the monthly cost of GLP-1 agonists, the government is testing the fiscal and clinical viability of mass-scale obesity management. The results of this 2026-2027 trial will likely determine if these medications become a permanent fixture of Medicare coverage or remain restricted to specific high-risk groups.
